Wide Ranks

AKBA

Akebia Therapeutics, Inc.

2.06

Top Statistics
Market Cap 449 M Forward PE -10.56 Revenue Growth -11.00 %
Current Ratio 1.52 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -27.07 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 117.60 Enterprise / Revenue 3.05 Price To Sales Trailing12 Months 2.65
Profitability
Profit Margins -27.07 % Operating Margins -33.41 %
Balance Sheet
Total Cash 34 M Total Cash Per Share 0.1560 Total Debt 103 M
Total Debt To Equity Current Ratio 1.52 Book Value Per Share -0.2380
All Measures
Short Ratio 487.00 % Message Board Id finmb_36644983 Fax 617 871 2099
Shares Short Prior Month 17 M City Cambridge Uuid f0f4b70d-7a99-33e9-84f9-09ab2c0b6996
Previous Close 2.05 First Trade Date Epoch Utc 1 B Book Value -0.2380
Beta 0.7340 Total Debt 103 M Volume 1 M
Fifty Two Week Low 0.8000 Total Cash Per Share 0.1560 Total Revenue 169 M
Shares Short Previous Month Date 1 B Target Median Price 5.00 Audit Risk 10
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -33.41 %
Target Mean Price 5.50 Net Income To Common -45992000 Short Percent Of Float 0.0554
Implied Shares Outstanding 218 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 34 M
Next Fiscal Year End 1 B Revenue Per Share 0.8340 Held Percent Insiders 0.0209
Ebitda Margins 2.60 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 8 Regular Market Previous Close 2.05
Target Low Price 4.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.59
Open 2.05 Free Cashflow 8 M State MA
Dividend Yield 0.00 % Return On Assets -0.0937 Time Zone Short Name EST
Board Risk 5 Trailing Eps -0.2200 Day Low 2.03
Address1 245 First Street Shares Outstanding 218 M Compensation Risk 9
Price Hint 4 Target High Price 7.50 Website https://www.akebia.com
52 Week Change 0.9434 Average Volume 1 M Forward Eps -0.2600
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 100.70 %
Is_sp_500 False Regular Market Day High 2.08 Profit Margins -27.07 %
Fifty Two Week High 2.48 Day High 2.08 Shares Short 11 M
Regular Market Open 2.05 Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 %
Enterprise To Revenue 3.05 Revenue Growth -11.00 % Shares Percent Shares Out 0.0548
Operating Cashflow -38501000 Currency USD Time Zone Full Name America/New_York
Market Cap 449 M Is_nasdaq_100 False Zip 02142
Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic Long Name Akebia Therapeutics, Inc.
Overall Risk 9 Regular Market Day Low 2.03 Held Percent Institutions 0.2728
Current Price 2.06 Address2 Suite 1400 Enterprise To Ebitda 117.60
Financial Currency USD Current Ratio 1.52 Gross Margins 84.13 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 3 Country United States
Float Shares 198 M Two Hundred Day Average 1.42 Governance Epoch Date 1 B
Enterprise Value 518 M Price To Sales Trailing12 Months 2.65 Forward PE -10.56
Regular Market Volume 1 M Ebitda 4 M Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.

The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.

It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.

The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth.

It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide.

Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.